Generated by AI
Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for prevalent retinal diseases with major unmet medical needs. The company’s lead program is TH103, an investigational anti-VEGF therapy designed for exudative and neovascular retinal conditions, including neovascular age-related macular degeneration. Kalaris Therapeutics also works on extending TH103’s use across other retinal disorders such as diabetic macular edema and retinal vein occlusion. Its current business centers on ophthalmology and biotechnology, where it aims to address sight-threatening diseases through targeted retinal therapies. The company is headquartered in the United States and operates as a specialist developer within the broader healthcare market.
Website400 Connell Drive
Berkeley Heights, NJ, 07922
United States
Summary of Jan 16's posts. Generated by AI.
Summary of Aug 21's posts. Generated by AI.
Summary of Dec 22's posts. Generated by AI.
Investors talking about ALVR also mention these. Each card shows that asset’s own numbers for the past 24 hours.